<DOC>
	<DOCNO>NCT02018406</DOCNO>
	<brief_summary>The purpose study determine safety efficacy combination erythropoietin ( EPO ) granulocyte-colony stimulate factor ( G-CSF ) patient neurological disease . To specific , clinical study expect combination injection EPO G-CSF show neurotrophic neuroprotective effect facilitate endogenous repair process patient neurological disease include stroke , cerebral palsy , atypical parkinsonism . Therefore , apply original treatment technique patient neurological disease , expect overcome current ethical technical limitation less evidenced functional recovery , hematological change , side effect . Eventually , We establish comprehensive clinical background neurotrophic neuroprotective effect hematopoietic growth factor therapy .</brief_summary>
	<brief_title>Establishment Clinical Basis Hematopoietic Growth Factors Therapy Brain Injury</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Over 20 year old Voluntary participant Neurological disease include stroke , cerebral palsy , atypical parkinsonism , least 3 month onset Participants get previous EPO+GCSF injection least 6 month ago . Under 20 year old Participants voluntarily consent Encephalopathy include brain tumor infection Warfarin ( coumadin ) medication Leukopenia , Thrombocytopenia , Polycythemia Malignant diseases , Malignant hypertension , Myeloproliferative disorder , Septic embolism , Hyperkalemia Hepatic Renal dysfunction , Serum creatinine &gt; 3mg/dl Allergic reaction exogenous EPO GCSF Involved exclusion criterion MRI test A woman pregnant breast feed Body temperature 38Â°C Blood pressure 140/90 mmHg pretreatment Blood pressure 160/100 mmHg intervention Hb &gt; 15 g/dL pretreatment Hb &gt; 17 g/dL intervention Pneumonia detect Xray test Recurrent history aspiration pneumonia</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Hematopoietic Growth Factors ( EPO , G-CSF ) ,</keyword>
	<keyword>Neurological Diseases ,</keyword>
	<keyword>Neurorehabilitation ,</keyword>
	<keyword>Neurotrophic Neuroprotective Effects</keyword>
</DOC>